Please login to the form below

Not currently logged in

HIV drug approved

Full marketing authorisation has been granted to Boehringer for its HIV protease inhibitor, Aptivus (tipranavir)
Full marketing authorisation has been granted to Boehringer for its HIV protease inhibitor (PI), Aptivus (tipranavir).

The European Commission has approved the drug, which has been developed to suppress HIV in treatment-experienced patients who have acquired a resistance to other PIs.

"This full approval demonstrates the confidence that the authorities have in the benefit of Aptivus for patients with a resistant virus," said Dr Andrea Barner, member of the board of Boehringer Ingelheim and responsible for research, development and medicine.

HIV has progressed to a point where a growing number of people across Europe are carrying strains of the disease which are resistant to various therapeutic options. Boehringer says that a study in Spain showed that 43 per cent of patients treated for more than eight years have more than five protease resistance mutations.

Aptivus is the first non-peptidic PI treatment and showed good anti-viral activity during trials. Over 1,400 patients were involved in two large studies, Resist I and II, located at different centres. It was the largest evaluation conducted to date of treatment-experienced patients, and proved the efficacy and safety of the medicine, which has been shown to combat drug-resistant strains of HIV.

7th May 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....